Denver Health Medical Center

Summary

Denver Health Medical Center is a medical facility located in Denver, Colorado. This center is recognized for care of Lung Cancer, Breast Cancer, Peroneal Nerve Injury, Breast cancer, Tuberculosis and other specialties. Denver Health Medical Center is involved with conducting 232 clinical trials across 480 conditions. There are 7 research doctors associated with this hospital, such as Ivor Douglas, MD, Ivor Douglass, MD, Jill Davies, MD, and Michael Hanley, MD.

Top PIs

Clinical Trials running at Denver Health Medical Center

Heart Attack

Chronic Hepatitis C

Opioid Overdose

Stable Angina

Coronary Artery Disease

Heart Failure

Cardiovascular Disease

Abdominal Aortic Aneurysm

Colon Cancer

Postpartum Depression

In-Person vs Telehealth Cardiac Rehab

for Heart Disease

Cardiac rehabilitation is a medically recommended program for patients with certain heart conditions. It includes exercise training, health education, and counseling. Unfortunately, many patients do not participate in cardiac rehabilitation. Some find it challenging to attend the in-person sessions. This study aims to compare two methods of delivering cardiac rehabilitation: in-person and through telehealth. The investigators want to know if the effects of these two programs are alike and if certain individuals benefit more from one program over the other.

Recruiting

1 award

N/A

5 criteria

Ziltivekimab

for Heart Attack

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant will need to inject the study medicine into a flat skin surface in there stomach, thigh, or upper arm once every month. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study will last for about 2 years.

Recruiting

1 award

Phase 3

5 criteria